Kuwait City, Kuwait, October 19, 2026: The International Testing Agency (ITA), on behalf of the Olympic Council of Asia (OCA), reports that Thai badminton player Pitchamon Opatniputh has been sanctioned for her anti-doping rules under the OCA anti-doping rules
As previously reported, a sample collected from badminton player Pitchamon Opatniputh during an out-of-competition anti-doping control on 17 September 2026 in Nagoya, Japan, returned an adverse analytical finding for furosemide.
Furosemide is prohibited under the WADA Prohibited List as S5 Diuretics and Masking Agents. It is prohibited at all times (in- and out-of-competition) and is classified as a specified substance. Furosemide can be used by athletes to excrete water for rapid weight loss.
Pursuant to the athlete’s request, on 24 September 2026, her B-sample was opened and analysed in the presence of an independent witness. The B-sample analysis confirmed the presence of furosemide.
The athlete accepted the consequences of her anti-doping rule violation (ADRV) under the OCA anti-doping rules (OCA ADR), namely (i) the finding of the ADRV, (ii) ineligibility for and exclusion from the Asian Games Aichi-Nagoya 2026 and (iii) loss of accreditation for the Asian Games Aichi-Nagoya 2026.
The matter is considered as concluded from the perspective of the OCA and has been referred to Badminton World Federation for a determination of further consequences.
There will be no further comments on this case.